Effectiveness of sacubitril–valsartan in cancer patients with heart failure

AIMS: Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy‐related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ESC Heart Fail
Asıl Yazarlar: Martín‐Garcia, Ana, López‐Fernández, Teresa, Mitroi, Cristina, Chaparro‐Muñoz, Marinela, Moliner, Pedro, Martin‐Garcia, Agustin C., Martinez‐Monzonis, Amparo, Castro, Antonio, Lopez‐Sendon, Jose L., Sanchez, Pedro L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Short Communications
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160493/
https://ncbi.nlm.nih.gov/pubmed/32022485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12627
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller